Form 4: Passage Bio CEO Sells Shares for Tax Obligations

Passage Bio's President and CEO, William Chou, reported the acquisition of 10,000 shares from RSU vesting and the subsequent sale of 4,076 shares to cover tax withholdings.

Summary

• William Chou, President and CEO of Passage BIO, Inc., reported transactions occurring on January 8, 2026.
• Acquired 10,000 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs).
• Sold 4,076 shares of common stock at a weighted average price of $18.4394 per share.
• The sale was an issuer-mandated "sell to cover" transaction to satisfy tax withholding obligations related to the RSU vesting, not a discretionary trade.
• Following these transactions, Chou directly beneficially owns 6,524 shares of common stock.
• The filing also notes that 50% of the total RSUs will vest on January 8, 2026, and the remaining 50% on January 8, 2027, contingent on continued service.
• Includes 600 shares acquired under the 2020 Employee Stock Purchase Plan across three dates: May 16, 2024, May 15, 2025, and November 15, 2025.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (RSU vesting and 'sell to cover' for taxes). While there's a reduction in direct ownership, it's not a discretionary sale, which mitigates negative sentiment. The continued vesting schedule indicates ongoing executive commitment.

Positives

• Vesting of 10,000 Restricted Stock Units (RSUs) for William Chou, indicating continued compensation and retention.
• The RSU vesting schedule extends to January 8, 2027, suggesting a commitment from the CEO to the company's long-term performance.

Negatives

• A portion of shares (4,076) were sold, reducing the CEO's direct beneficial ownership from 10,600 to 6,524 shares after the RSU conversion and sale.

Future Outlook

The vesting schedule for William Chou's remaining Restricted Stock Units extends to January 8, 2027, contingent on his continued provision of service to Passage BIO, Inc.

Management Comments

• The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person.
• Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.

Industry Context

This Form 4 filing details routine executive compensation transactions, specifically the vesting of Restricted Stock Units and the subsequent 'sell to cover' sale for tax purposes. Such transactions are common across the biotechnology and pharmaceutical industries for executive incentive plans and do not inherently reflect a change in company strategy or market position.

Stakeholder Impact

• Shareholders: Slight dilution from RSU vesting (already accounted for in outstanding shares), but the "sell to cover" is a common practice and not a signal of lack of confidence. The CEO's continued RSU vesting schedule suggests ongoing alignment with shareholder interests.
• Employees: The mention of the 2020 Employee Stock Purchase Plan (ESPP) indicates a broader employee benefit program.

Next Steps

• Remaining 50% of William Chou's RSUs are scheduled to vest on January 8, 2027, subject to continued service.

Key Dates

Recommendation

The filing details a standard 'sell to cover' transaction by the CEO to satisfy tax obligations upon RSU vesting. This is a non-discretionary sale and does not signal a change in management's outlook or company fundamentals. The continued vesting schedule for future RSUs suggests ongoing executive commitment. Therefore, the filing itself does not provide new information warranting a change in investment stance, maintaining a 'hold' recommendation based solely on this report.

Keywords

Passage BIO, PASG, William Chou, Form 4, Insider Trading, SEC Filing, Restricted Stock Units, RSU Vesting, Sell to Cover, Executive Compensation, Stock Transaction